Put companies on watchlist
Eckert & Ziegler Strahlen- und Medizintechnik AG
ISIN: DE0005659700
WKN: 565970
About
Company Snapshot
New: Enable Investor Alerts
Be informed about new publications
New: AI Factsheet

Corporate News meets AI! 
Content analysis and summary

EN GIF 300X250

Eckert & Ziegler Strahlen- und Medizintechnik AG · ISIN: DE0005659700 · EQS - Company News (122 News)
Country: Germany · Primary market: Germany · EQS NID: 1652023
07 June 2023 05:18PM

Annual General Meeting Approves Dividend of EUR 0.50 per Share. Reorganization of the Executive Board, Supervisory Board and Group Executive Committee.


EQS-News: Eckert & Ziegler Strahlen- und Medizintechnik AG / Key word(s): AGM/EGM/Personnel
ckert & Ziegler: Annual General Meeting Approves Dividend of EUR 0.50 per Share. Reorganization of the Executive Board, Supervisory Board and Group Executive Committee.

07.06.2023 / 17:18 CET/CEST
The issuer is solely responsible for the content of this announcement.


Berlin, 7 June 2023. At today's Annual General Meeting of Eckert & Ziegler AG, the shareholders approved the proposal of the Executive Board and Supervisory Board to distribute a dividend of 0.50 EUR per dividend-bearing share. All items on the agenda were accepted by the shareholders. A total of 57.75% of the share capital of Eckert & Ziegler AG was represented at the Annual General Meeting.

At the end of the Annual General Meeting, the former Chairman of the Executive Board and founder Dr. Andreas Eckert (63) moved to the Supervisory Board. As planned, Dr. Harald Hasselmann (56), member of the Executive Board and responsible for the Medical segment, thus takes over as Chairman of the Executive Board. The long-standing Chairman of the Supervisory Board, Prof. Dr. Wolfgang Maennig, left the Supervisory Board at the end of the Annual General Meeting.

At his own request and as part of an early retirement arrangement, Dr. Lutz Helmke is leaving the Executive Board. Newly appointed to the Executive Board and responsible for the Isotopes segment is the long-time head of this division, Frank Yeager, who is based in California. The Executive Board positions of Dr. Hakim Bouterfa and Jutta Ludwig remain unaffected by the changes. A new member of the Executive Committee will be Ana Ramirez, for many years General Manager within the Isotope Products segment and responsible, among others, for the Latin American business.

The documents and voting results for the Annual General Meeting are available at Eckert & Ziegler Strahlen- und Medizintechnik AG: Annual General Meeting (ezag.com)


About Eckert & Ziegler.
Eckert & Ziegler Strahlen- und Medizintechnik AG with more than 1.000 employees is a leading specialist for isotope-related components in nuclear medicine and radiation therapy. The company offers a broad range of services and products for the radiopharmaceutical industry, from early development work to contract manufacturing and distribution. Eckert & Ziegler shares (ISIN DE0005659700) are listed in the TecDAX index of Deutsche Börse.
Contributing to saving lives.

Your contact:
Eckert & Ziegler AG, Karolin Riehle, Investor Relations
Robert-Rössle-Str. 10, 13125 Berlin, Germany
Tel.: +49 (0) 30 / 94 10 84-138, karolin.riehle@ezag.de, www.ezag.com 

 



07.06.2023 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


Language: English
Company: Eckert & Ziegler Strahlen- und Medizintechnik AG
Robert-Rössle-Str.10
13125 Berlin
Germany
Phone: +49 30 941084-138
Fax: +49 30 941084-112
E-mail: karolin.riehle@ezag.de
Internet: www.ezag.de
ISIN: DE0005659700
WKN: 565970
Indices: SDAX, TecDAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 1652023

 
End of News EQS News Service

1652023  07.06.2023 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1652023&application_name=news&site_id=boersengefluester
Visual performance / price development - Eckert & Ziegler Strahlen- und Medizintechnik AG
Smart analysis and research tools can be found here.

This publication was provided by our content partner EQS3.

EQS Newswire
via EQS - Newsfeed
EQS Group AG ©2024
(DGAP)
Contact:
Karlstraße 47 D-80333 München
+49 (0) 89 444 430-000

 

SMART * AD
EN GIF 970X250

P R O D U C T   S U G G E S T I O N S

The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.


The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.

If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.

For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.


1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.